Dr. Cotter, a board-certified dermatologist at Las Vegas Dermatology, presents a real-world case of Prurigo Nodularis, highlighting both the severity of disease presentation and the impact of targeted therapy. The patient presented with over 100 lesions and had previously failed multiple lines of treatment.
Dr. Cotter initiated therapy with Nemolizumab, a targeted biologic, as the next-line option. The patient achieved complete clearance by Week 16, exceeding the 25% to 40% clearance rates typically reported in clinical trials.
Topics Covered
- Clinical presentation and disease burden in prurigo nodularis
- Challenges in managing treatment-refractory cases
- Real-world outcomes with nemolizumab therapy
- Review of clinical trial data and expected efficacy benchmarks
- Recommended dosing strategies for nemolizumab
Explore Related Resources
